AR123705A1 - Moduladores del regulador de conductancia transmembranario de la fibrosis quística - Google Patents

Moduladores del regulador de conductancia transmembranario de la fibrosis quística

Info

Publication number
AR123705A1
AR123705A1 ARP210102775A ARP210102775A AR123705A1 AR 123705 A1 AR123705 A1 AR 123705A1 AR P210102775 A ARP210102775 A AR P210102775A AR P210102775 A ARP210102775 A AR P210102775A AR 123705 A1 AR123705 A1 AR 123705A1
Authority
AR
Argentina
Prior art keywords
modulators
cystic fibrosis
conductance regulator
transmembrane conductance
pharmaceutical compositions
Prior art date
Application number
ARP210102775A
Other languages
English (en)
Inventor
Jason Mcartney
Alexander Russell Abela
Sunny Abraham
Corey Don Anderson
Vijayalaksmi Arumugam
Jaclyn Chau
Jeremy Clemens
Thomas Cleveland
Timothy A Dwight
Bryan A Frieman
Peter Fallecido Grootenhuis
Ruah Sara Sabina Hadida
Yoshihiro Ishihara
Paul Krenitsky
Mark Thomas Miller
Fabrice Pierre
Alina Silina
Jinglan Zhou
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of AR123705A1 publication Critical patent/AR123705A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Esta descripción proporciona moduladores del regulador de conductancia transmembranario de la fibrosis quística (CFTR), composiciones farmacéuticas que contienen al menos uno de tales moduladores, métodos de tratamiento de la fibrosis quística mediante el uso de tales moduladores y composiciones farmacéuticas, y procesos para producir tales moduladores.
ARP210102775A 2020-10-07 2021-10-07 Moduladores del regulador de conductancia transmembranario de la fibrosis quística AR123705A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063088636P 2020-10-07 2020-10-07

Publications (1)

Publication Number Publication Date
AR123705A1 true AR123705A1 (es) 2023-01-04

Family

ID=78483539

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102775A AR123705A1 (es) 2020-10-07 2021-10-07 Moduladores del regulador de conductancia transmembranario de la fibrosis quística

Country Status (6)

Country Link
US (1) US20230365587A1 (es)
EP (1) EP4225762A1 (es)
AR (1) AR123705A1 (es)
TW (1) TW202222306A (es)
UY (1) UY39455A (es)
WO (1) WO2022076618A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202333699A (zh) 2022-02-03 2023-09-01 美商維泰克斯製藥公司 囊腫纖維化之治療方法
IL314691A (en) 2022-02-03 2024-10-01 Vertex Pharmaceuticals Incorporated PREPARATION METHODS AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[ 12.3.112.3.1. NONADECA-1(18),2,4,14,16-PENTAEN-6-OL
WO2023224931A1 (en) 2022-05-16 2023-11-23 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202421102A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合
TW202421636A (zh) 2022-09-15 2024-06-01 瑞士商愛杜西亞製藥有限公司 (3S,7S,10R,13R)-13-苄基-20-氟-7-異丁基-N-(2-(3-甲氧基-1,2,4-㗁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四側氧基-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氫-[1]㗁[4,7,10,14]四氮雜環十七烷并[16,17-f]喹啉-3-甲醯胺的晶型
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
PT2502911T (pt) 2004-06-24 2017-07-10 Vertex Pharma Moduladores de transportadores de cassete de ligação de atp
SI1945632T1 (sl) 2005-11-08 2014-03-31 Vertex Pharmaceuticals Incorporated Heterocikliäśni modulatorji za prenaĺ alce z atp-vezavno kaseto
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
ES2377840T3 (es) 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
PL2231606T3 (pl) 2007-12-07 2013-07-31 Vertex Pharma Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych
UA102534C2 (en) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]-dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
ME03019B (me) 2008-08-13 2018-10-20 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1- dimeтileтil)-5-hidroksifenil]- 1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
CA2736545A1 (en) 2008-09-29 2010-04-01 Vertex Pharmaceuticals Incorporated Dosage units of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
DK2365972T3 (en) 2008-11-06 2015-01-19 Vertex Pharma Modulators of atp-binding cassette conveyors
MX2011009867A (es) 2009-03-20 2012-01-12 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quistica.
NZ602665A (en) 2010-03-25 2014-10-31 Vertex Pharma Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihyderoxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
WO2011127421A1 (en) 2010-04-09 2011-10-13 Berkeley Bionics Exoskeleton load handling system and method of use
CA2796642A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
KR20190061096A (ko) 2010-04-22 2019-06-04 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
US20120064157A1 (en) 2010-08-27 2012-03-15 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
EP3235812B1 (en) 2011-05-18 2019-09-04 Vertex Pharmaceuticals (Europe) Limited Deuterated derivatives of ivacaftor
MX2014010253A (es) 2012-02-27 2014-11-12 Vertex Pharma Composicion farmaceutica y administraciones de la misma.
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SG10201703452PA (en) 2012-11-02 2017-06-29 Vertex Pharma Pharmaceutical compositions for the treatment of cftr mediated diseases
MY183582A (en) 2012-11-19 2021-02-26 Vertex Pharmaceuticals Europe Ltd Deuterated cftr potentiators
RS64400B1 (sr) 2014-04-15 2023-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
US20180353500A1 (en) 2015-09-21 2018-12-13 Vertex Pharmaceuticals (Europe) Limited Administration of deuterated cftr potentiators
AU2017352206B2 (en) 2016-10-27 2022-03-03 Vertex Pharmaceuticals (Europe) Limited Methods of treatment with deuterated CFTR potentiators
BR112020015509A2 (pt) * 2018-02-15 2021-01-26 Vertex Pharmaceuticals Incorporated macrociclos como moduladores de regulador da condutância transmembrana da fibrose cística, composições farmacêuticas dos mesmos, sua utilização no tratamento da fibrose cística, e processo para sua produção
TWI848092B (zh) * 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
KR20220064366A (ko) * 2019-08-14 2022-05-18 버텍스 파마슈티칼스 인코포레이티드 Cftr 조절제의 결정질 형태

Also Published As

Publication number Publication date
WO2022076618A1 (en) 2022-04-14
UY39455A (es) 2022-05-31
EP4225762A1 (en) 2023-08-16
US20230365587A1 (en) 2023-11-16
TW202222306A (zh) 2022-06-16

Similar Documents

Publication Publication Date Title
UY39374A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
AR123708A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123706A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123707A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123709A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123710A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123711A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
AR123705A1 (es) Moduladores del regulador de conductancia transmembranario de la fibrosis quística
CO2022002749A2 (es) Moduladores del regulador de conductancia transmembrana de la fibrosis quística
ECSP23045439A (es) Macrociclos que contienen un anillo de 1,3,4-oxadiazol para su uso como moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CL2011000919A1 (es) Compuestos derivados de n-fenil-4-oxo-(1,4-dihidroquinolin o 1h-quinolin)-3-carboxamida, moduladores del regulador de conductancia transmembrana de fibrosis quistica (cftr); compuestos intermediarios; composicion farmaceutica; kit farmaceutico; proceso de preparacion; y uso para el tratamiento de fibrosis quistica, diabetes, entre otros.
UY39521A (es) Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
BR112018011767A2 (pt) aparelho e processo de separação através de espuma

Legal Events

Date Code Title Description
FB Suspension of granting procedure